Literature DB >> 6700630

Emetine myopathy: two case reports with pathobiochemical analysis.

H Sugie, R Russin, M A Verity.   

Abstract

We report two female patients with a history of alcohol abuse presenting with proximal painful muscle weakness following aversion therapy with emetine hydrochloride. Muscle biopsy of Case 1 showed a reversible floccular-shaped loss of myosin ATPase and dehydrogenase, an accumulation of PAS positive material, and a normal lipid content. Repeat biopsy showed core change with no focal loss of myosin ATPase. In Case 2, muscle biopsy was taken 1 month after commencement of emetine therapy and revealed similar but milder changes to Case 1. Electron microscopy revealed Z-band streaming with a decrease or loss of mitochondria. Sarcotubular systems appeared normal in shape and size. Anaerobic glycolysis on homogenate from the initial biopsy of Case 1 showed generalized reduction of lactate formation, which returned to normal in the repeat biopsy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6700630     DOI: 10.1002/mus.880070109

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  8 in total

1.  Emetine-induced myopathy and carnitine deficiency.

Authors:  T Kuntzer; H Reichmann; J Bogousslavsky; F Regli
Journal:  J Neurol       Date:  1990-12       Impact factor: 4.849

2.  A rapid, high-throughput viability assay for Blastocystis spp. reveals metronidazole resistance and extensive subtype-dependent variations in drug susceptibilities.

Authors:  Haris Mirza; Joshua D W Teo; Jacqui Upcroft; Kevin S W Tan
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

3.  Myopathy from surreptitious ipecac ingestion.

Authors:  N L Rosenberg; S P Ringel
Journal:  West J Med       Date:  1986-09

4.  Absorption, distribution and excretion of 3H-labeled cephaeline- and emetine-spiked ipecac syrup in rats.

Authors:  Takayuki Asano; Kazuhisa Ishihara; Yoko Wakui; Toshihiko Yanagisawa; Masayuki Kimura; Hideo Kamei; Takemi Yoshida; Yukio Kuroiwa; Yuichi Fujii; Mamoru Yamashita; Takanori Kuramochi; Hiroki Tomisawa; Mitsuru Tateishi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

5.  Experimental emetine myopathy: enzyme histochemical, electron microscopic, and immunomorphological studies.

Authors:  N J Hopf; H H Goebel
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

6.  Ipecac myopathy and cardiomyopathy.

Authors:  L P Dresser; E W Massey; E E Johnson; E Bossen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

7.  Reversible emetine-induced myopathy with ECG abnormalities: a toxic myopathy.

Authors:  T Kuntzer; J Bogousslavsky; J P Deruaz; R Janzer; F Regli
Journal:  J Neurol       Date:  1989-05       Impact factor: 4.849

8.  Biotransformation of the ipecac alkaloids cephaeline and emetine from ipecac syrup in rats.

Authors:  Takayuki Asano; Junko Watanabe; Chiharu Sadakane; Kazuhisa Ishihara; Kazuhiro Hirakura; Yoko Wakui; Toshihiko Yanagisawa; Masayuki Kimura; Hideo Kamei; Takemi Yoshida; Yuichi Fujii; Mamoru Yamashita
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.